2004S-0170 - Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Section 1013: Suggest Priority Topics for Research
FDA Comment Number : EC19
Submitter : Dr. Glen Stanbaugh Date & Time: 05/11/2004 06:05:29
Organization : Texas Renal Coalition
Health Professional
Category :
Issue Areas/Comments
This email is being submitted to HHS on behalf of the Texas Renal
Coalition, a statewide advocacy organization committed to helping the more
than 25,000 kidney patients within our State who depend on Medicare
services, and more than 6000 kidney patients who depend on Medicaid services through the State Medicaid Program. We are vitally concerned about the ongoing service and resesarch needs of patients with kidney disease, and we encourage you to keep them at the forefront of your resesearch priorities. As well, however, the criterion of "cost-effectiveness" in light of serving complicated and serious medical populations such as persons with kidney disease is of concern to us. Obviously generic drugs cannot always meet the needs of kidney patients. As such, we would encourage you to make certain that the individual needs of kidney patients remain at the forefront of all research and service
delivery decisions as you move forward. Our organization stands ready to
work with you. Thank you, Dr. Glen Stanbaugh, Board President, Mrs. Rita
Littlefield, Board Secretary, Texas Renal Coalition, Austin, TX